• 1
    Cooper JS, Porter K, Mallin K, et al. National Cancer Database report on cancer of the head and neck: 10-year update. Head Neck. 2009;31:748-758.
  • 2
    Beck SL. Mucositis. In: Yarbro CH, Frogge MH, Goodman M, eds. Cancer Symptom Management. 3rd edition. Sudbury, MA: Jones and Bartlett; 2004:765.
  • 3
    Given B, Given C, Azzouz F, Stommel M. Physical functioning of elderly cancer patients prior to diagnosis and following initial treatment. Nurs Res. 2001;50:222-232.
  • 4
    Xiao C, Hanlon A, Zhang Q, et al. Symptom clusters in patients with head and neck cancer receiving concurrent chemoradiotherapy. Oral Oncol. 2013;49:360-366.
  • 5
    Wang SY, Tsai CM, Chen BC, Lin CH, Lin CC. Symptom clusters and relationships to symptom interference with daily life in Taiwanese lung cancer patients. J Pain Symptom Manage. 2008;35:258-266.
  • 6
    Kim HJ, Barsevick AM, Tulman L. Predictors of the intensity of symptoms in a cluster in patients with breast cancer. J Nurs Scholarsh. 2009;41:158-165.
  • 7
    Fleming ID, Cooper JS, Henson DE, et al. AJCC Cancer Staging Manual. 5th edition. Philadelphia, PA: Lippincott Williams & Wilkins; 1997.
  • 8
    Wainer H. Estimating coefficients in linear models: It don't make no nevermind. Psychol Bull. 1976;83:213-217.
  • 9
    Thorndike RL. Applied Psychometrics. Boston, MA: Houghton Mifflin; 1982.
  • 10
    Elting LS, Cooksley CD, Chambers MS, Garden AS. Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys. 2007;68:1110-1120.
  • 11
    Vera-Llonch M, Oster G, Hagiwara M, Sonis S. Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma. Cancer. 2006;106:329-336.
  • 12
    Corvo R. Evidence-based radiation oncology in head and neck squamous cell carcinoma. Radiother Oncol. 2007;85:156-170.
  • 13
    Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000;48:7-16.
  • 14
    Mortensen HR, Overgaard J, Specht L, et al. Prevalence and peak incidence of acute and late normal tissue morbidity in the DAHANCA 6&7 randomised trial with accelerated radiotherapy for head and neck cancer. Radiother Oncol. 2012;103:69-75.
  • 15
    Overgaard J, Mohanti BK, Begum N, et al. Five versus six fractions of radiotherapy per week for squamous-cell carcinoma of the head and neck (IAEA-ACC study): a randomised, multicentre trial. Lancet Oncol. 2010;11:553-560.
  • 16
    Chitapanarux I, Tharavichitkul E, Kamnerdsupaphon P, Pukanhapan N, Vongtama R. Randomized phase III trial of concurrent chemoradiotherapy vs accelerated hyperfractionation radiotherapy in locally advanced head and neck cancer. J Radiat Res. 2013;54:1110-1117.
  • 17
    Yoon J, Malin JL, Tao ML, et al. Symptoms after breast cancer treatment: are they influenced by patient characteristics? Breast Cancer Res Treat. 2008;108:153-165.
  • 18
    Stanton AL, Bernaards CA, Ganz PA. The BCPT symptom scales: a measure of physical symptoms for women diagnosed with or at risk for breast cancer. J Natl Cancer Inst. 2005;97:448-456.
  • 19
    Green CR, Hart-Johnson T, Loeffler DR. Cancer-related chronic pain: examining quality of life in diverse cancer survivors. Cancer. 2011;117:1994-2003.
  • 20
    Eversley R, Estrin D, Dibble S, Wardlaw L, Pedrosa M, Favila-Penney W. Post-treatment symptoms among ethnic minority breast cancer survivors. Oncol Nurs Forum. 2005;32:250-256.
  • 21
    Cleeland CS, Gonin R, Baez L, Loehrer P, Pandya KJ. Pain and treatment of pain in minority patients with cancer. The Eastern Cooperative Oncology Group Minority Outpatient Pain Study. Ann Intern Med. 1997;127:813-816.
  • 22
    Berkman ND, Sheridan SL, Donahue KE, Halpern DJ, Crotty K. Low health literacy and health outcomes: an updated systematic review. Ann Intern Med. 2011;155:97-107.
  • 23
    Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 2004;291:2720-2726.
  • 24
    Lockwood-Rayermann S, Donovan HS, Rambo D, Kuo CW. Women's awareness of ovarian cancer risks and symptoms. Am J Nurs. 2009;109:36-45.
  • 25
    David MM, Ko L, Prudent N, Green EH, Posner MA, Freund KM. Mammography use. J Natl Med Assoc. 2005;97:253-261.
  • 26
    Movsas B, Scott C, Watkins-Bruner D. Pretreatment factors significantly influence quality of life in cancer patients: a Radiation Therapy Oncology Group (RTOG) analysis. Int J Radiat Oncol Biol Phys. 2006;65:830-835.
  • 27
    Cheung WY, Le LW, Gagliese L, Zimmermann C. Age and gender differences in symptom intensity and symptom clusters among patients with metastatic cancer. Support Care Cancer. 2011;19:417-423.
  • 28
    Liaw CC, Chang HK, Liau CT, Huang JS, Lin YC, Chen JS. Reduced maintenance of complete protection from emesis for women during chemotherapy cycles. Am J Clin Oncol. 2003;26:12-15.
  • 29
    Feyer P, Maranzano E, Molassiotis A, Roila F, Clark-Snow RA, Jordan K. Radiotherapy-induced nausea and vomiting (RINV): MASCC/ESMO guideline for antiemetics in radiotherapy: update 2009. Support Care Cancer. 2011;19(suppl 1):S5-S14.
  • 30
    Fraunholz I, Grau K, Weiss C, Rödel C. Patient- and treatment-related risk factors for nausea and emesis during concurrent chemoradiotherapy. Strahlenther Onkol. 2011;187:1-6.
  • 31
    Hesketh PJ, Grunberg SM, Herrstedt J, et al. Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer. 2006;14:354-360.
  • 32
    Myles PS, Hunt JO, Moloney JT. Postoperative ‘minor' complications. Comparison between men and women. Anaesthesia. 1997;52:300-306.
  • 33
    Brattwall M, Warrén Stomberg M, Rawal N, Segerdahl M, Houltz E, Jakobsson J. Postoperative impact of regular tobacco use, smoking or snuffing, a prospective multi-center study. Acta Anaesthesiol Scand. 2010;54:321-327.
  • 34
    Ionescu D, Badescu C, Acalovschi I. Nicotine patch for the prevention of postoperative nausea and vomiting: a prospective randomised trial. Clin Drug Investig. 2007;27:559-564.
  • 35
    Greenland S, Satterfield MH, Lanes SF. A meta-analysis to assess the incidence of adverse effects associated with the transdermal nicotine patch. Drug Saf. 1998;18:297-308.
  • 36
    Zhan M, Flaws JA, Gallicchio L, Tkaczuk K, Lewis LM, Royak-Schaler R. Profiles of tamoxifen-related side effects by race and smoking status in women with breast cancer. Cancer Detect Prev. 2007;31:384-390.
  • 37
    Czarnetzki C, Schiffer E, Lysakowski C, Haller G, Bertrand D, Tramer MR. Transcutaneous nicotine does not prevent postoperative nausea and vomiting: a randomized controlled trial. Br J Clin Pharmacol. 2011;71:383-390.
  • 38
    Basch E, Bennett A, Pietanza MC. Use of patient-reported outcomes to improve the predictive accuracy of clinician-reported adverse events. J Natl Cancer Inst. 2011;103:1808-1810.